Search results
Results from the WOW.Com Content Network
Many of these infections are less serious, but the Centers for Disease Control and Prevention (CDC) estimate that there are 80,461 invasive MRSA infections and 11,285 deaths due to MRSA annually. [109] In 2003, the cost for a hospitalization due to MRSA infection was US$92,363; a hospital stay for MSSA was $52,791. [89]
In October 2010, FDA approval was gained for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, including MRSA. [15] MRSA can develop resistance to ceftaroline through the alteration of penicillin-binding proteins.
First-line treatment for serious invasive infections due to MRSA is currently glycopeptide antibiotics (vancomycin and teicoplanin). A number of problems with these antibiotics occur, such as the need for intravenous administration (no oral preparation is available), toxicity, and the need to monitor drug levels regularly by blood tests.
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 Clinical Trial to Initiate in 4Q19 On October 2, 2019, ContraFect Corp. (NASDAQ:CFRX) announced that ...
Dalbavancin is an antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults caused by susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections have become problematic in the community and in healthcare settings due to resistance to many available ...
(Reuters) -The U.S. Food and Drug Administration has approved Verrica Pharmaceuticals Inc's treatment of a viral skin infection in adults and children aged 2 years and above, the company said on ...
But, each type of skin infection caused by staph bacteria is different. A few common skin infections caused by staph bacteria are: Boils – Boils are the most common type of staph infection, they are pockets of white pus that start where a hair follicle or oil gland is. The boil is tender and red where the infection is located on the skin.
Rib-X Pharmaceuticals, Inc. is a biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections.